Sara Nik, an analyst from H.C. Wainwright, has initiated a new Buy rating on Cantargia AB (7V3).
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sara Nik’s rating is based on Cantargia AB’s promising pipeline in both oncology and autoimmune indications. The company’s lead asset, nadunolimab, is being tested in several challenging cancers, including metastatic pancreatic ductal adenocarcinoma (PDAC), where it shows potential to compete with existing treatments if its mechanism proves effective. This positions Cantargia to offer multiple value drivers to investors, making it an attractive long-term investment.
Additionally, the acquisition of Cantargia’s CAN10 program by Otsuka Pharmaceutical provides significant external validation and financial support. This deal not only brings upfront cash but also potential milestone payments and royalties, allowing Cantargia to focus on its core strengths while reducing its R&D burden. The strategic partnership with Otsuka enhances Cantargia’s financial stability and supports further development of its promising oncology programs, contributing to the Buy rating.